Geron stock weighs revenue growth against a USD 1.21 price

Published on 10/07/2026 at 06:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 57.5 million, up 17 percent year over year, for the period ended June 30, 2026. Geron stock carries a five-analyst Hold consensus with a USD 4.00 target.

GERN, US3741631036, Illustration mit AI erstellt.

Geron stock was last at USD 1.21 on Nasdaq on October 6, 2026, while its market capitalization stood at USD 776.2 million. The valuation sits against a commercial update that delivered higher revenue but left the company in a loss-making position.

RYTELO revenue keeps growing

For Q2 2026, net revenue reached USD 57.5 million, up 17 percent from the year-earlier quarter and 11 percent from Q1 2026, according to Quartr. The Q2 period ended June 30, 2026, and marked the third consecutive quarter of revenue growth.

The same conference summary reports first-half revenue growth of 24 percent and a 4 percent reduction in operating expenses. That combination is important because Geron is trying to move RYTELO from an early commercial launch into a broader treatment routine for lower-risk myelodysplastic syndromes.

Guidance points toward the upper end

Geron's 2026 RYTELO net revenue guidance remains USD 220 million to USD 240 million, while management expects results at the mid to high end of that range, according to MarketBeat. Operating expense guidance is also USD 230 million to USD 240 million for 2026, placing spending close to the projected product revenue range.

Commercial execution is shifting toward community oncology practices, where adoption can expand beyond the academic centers that supported the initial launch. The company also continues a 327-patient Phase 3 myelofibrosis study, making clinical progress a separate valuation driver from near-term RYTELO sales.

Consensus stays far above the quote

MarketBeat lists a five-analyst Hold consensus and an average target of USD 4.00. That target lies 230.6 percent above the USD 1.21 price on October 6, 2026, but the same source says Q2 adjusted earnings per share missed consensus at negative USD 0.02 versus negative USD 0.01, even as revenue exceeded estimates.

The split between stronger sales and continuing losses defines the stock's risk profile. Q2 net income was a loss of USD 16.7 million, compared with a loss of USD 3.6 million in Q1 2026, according to the quarterly financial data for Geron.

Geron stock remains near its yearly low

Geron stock traded at USD 1.21 on Nasdaq on October 6, 2026, with volume of 5,718,045 shares. Its 52-week range was USD 1.04 to USD 2.01, leaving the quote 16.3 percent above the low and 39.8 percent below the high.